Beyond Tint

BACKGROUNDPost-inflammatory hyperpigmentation (PIH) is among the most burdensome sequelae of inflammatory dermatoses in skin of color (SOC), and reduction of visible pigmentation represents the primary clinical outcome of interest. Tinted sunscreens containing iron oxides and/or pigmentary titanium dioxide are currently the best-evidenced strategy for preventing visible light-driven PIH in SOC. However, cosmetic unacceptability-including white cast, poor shade match, and texture incompatibility with acne-prone skin-significantly limits real-world adherence. This concept paper proposes a clinical reframing: when pigment-based visible light filters are not tolerated, pigmentation reduction may be achievable through proactive topical actives with direct anti-pigmentation activity.

METHODSThis commentary synthesizes the mechanistic and clinical literature on high-energy visible light (HEVL)-driven pigmentation in SOC, with particular focus on the opsin-3-MITF-melanogenesis axis and topical actives with demonstrated anti-pigmentation activity against HEVL-induced melanogenesis. Evidence is presented to support a proposed clinical reframing and pragmatic algorithm.

RESULTSHEVL activates opsin-3 on melanocytes, upregulating MITF and promoting formation of stable, autophagy-resistant melanosomes-a mechanism distinct from UVA-driven photooxidation and particularly relevant in darker phototypes. Four prototypical actives with direct clinical or preclinical evidence against HEVL-induced pigmentation are reviewed.

CONCLUSIONPigmentation reduction-rather than the mechanism by which it is achieved-should be recognized as the primary clinical endpoint in photoprotection for PIH in SOC. When pigment-based visible light filters containing iron oxides and/or pigmentary titanium dioxide are cosmetically unacceptable, a strategy combining broad-spectrum UVA1 photoprotection with a topical active with anti-pigmentation activity represents a rational, evidence-informed alternative that keeps the clinical goal firmly in focus.

Abstract from PubMed